Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 20/20 | 0.81 |
| ▸ | GABRB3 | P28472 | 20/20 | 0.81 |
| ▸ | GABRA3 | P34903 | 20/20 | 0.81 |
| ▸ | GABRA1 | P14867 | 12/20 | 0.81 |
| ▸ | GABRA2 | P47869 | 9/20 | 0.81 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7960048 | 0.91 | GABRG2 (0.68) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL7960427 | 0.91 | GABRG2 (0.67) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL6774410 | 0.91 | GABRG2 (0.67) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL2655133 | 0.90 | GABRG2 (0.66) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL7972253 | 0.90 | GABRG2 (0.66) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL340744 | 0.90 | GABRG2 (1.00) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL7959492 | 0.88 | GABRG2 (0.63) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL6769113 | 0.88 | GABRG2 (0.63) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL6773626 | 0.88 | GABRG2 (0.62) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL6773408 | 0.87 | GABRG2 (0.62) | GABRG2GABRB3GABRA3GABRA1GABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058267-A1 | Pharmaceutical compositions comprising a NOS inhibitor | PFIZER INC | 2006-03-16 | — | — | US | claimed |
| EP-0915875-B1 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2003-04-09 | — | — | EP | claimed |
| US-20030045449-A1 | Pharmaceutical combinations for the treatment of neurodegenerative diseases | PFIZER, INC. | 2003-03-06 | — | — | US | claimed |
| US-20020165217-A1 | Combination treatment for anxiety and depression | PFIZER INC. | 2002-11-07 | — | — | US | claimed |
| EP-1254668-A2 | Combination of a serotonin reuptake inhibitor and a GABA-A alpha 2/3 agonist for use in anxiety and depression | Pfizer Products Inc. (US) | 2002-11-06 | — | — | EP | claimed |
| US-6255305-B1 | PSYCHOLOGICAL DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 2001-07-03 | — | — | US | claimed |
| US-6174886-B1 | TREATMENT AND/OR PREVENTION OF PSYCHOTIC DISORDERS INCLUDING SCHIZOPHRENIA WITH REDUCED SEDATION; SELECTIVE LIGANDS FOR GAMMA-AMINOBUTYRIC ACID A RECEPTORS, IN PARTICULAR HAVING HIGH AFFINITY FOR THE ALPHA2 AND/OR ALPHA3 SUBUNIT | MERCK SHARP & DOHME LTD. (GB) | 2001-01-16 | — | — | US | claimed |
| US-6110915-A | Antiemetic use of triazolo-pyridazine derivatives | MERCK & CO., INC. (US) | 2000-08-29 | — | — | US | claimed |
| US-6107296-A | Neuroprotective use of triazolo-pyridazine derivatives | MERCK SHARP & DOHME, LTD. (GB) | 2000-08-22 | — | — | US | claimed |
| US-6063783-A | Analgesic use of triazolo-pyridazine derivatives | MERCK SHARP & DOHME LTD. (GB) | 2000-05-16 | — | — | US | claimed |
| US-6046196-A | Antispastic use of triazolo-pyridazine derivatives | MERCK SHARP & DOHME LTD. (GB) | 2000-04-04 | — | — | US | claimed |
| WO-1999025353-A1 | THERAPEUTIC USES OF TRIAZOLO-PYRIDAZINE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1999-05-27 | — | — | WO | claimed |
| EP-0915875-A2 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 1999-05-19 | — | — | EP | claimed |
| WO-1998004559-A2 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 1998-02-05 | — | — | WO | claimed |
| US-10485814-B2 | Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-11-26 | — | — | US | disclosed |
| US-20170189433-A1 | NICOTINAMIDE RIBOSIDE ANALOGS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-07-06 | — | — | US | disclosed |
| EP-3149016-A1 | PREPARATION AND USE OF CRYSTALLINE BETA-D-NICOTINAMIDE RIBOSIDE | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2017-04-05 | — | — | EP | disclosed |
| WO-1999025353-A1 | THERAPEUTIC USES OF TRIAZOLO-PYRIDAZINE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1999-05-27 | — | — | WO | disclosed |
| EP-0915875-A2 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 1999-05-19 | — | — | EP | disclosed |
| WO-1998004559-A2 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 1998-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165217-A1 | Combination treatment for anxiety and depression | GABRA1, GABRA2, GABRA5 | GABRG2 20/4885GABRB3 10/4885GABRA3 6/4885 |
| US-20170189433-A1 | NICOTINAMIDE RIBOSIDE ANALOGS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | NNT, CS, ME2 | GABRG2 3777/4885GABRB3 2740/4885GABRA3 3221/4885 |
| US-20060058267-A1 | Pharmaceutical compositions comprising a NOS inhibitor | NOS1, NOS2, NOS3 | GABRG2 18/4885GABRB3 7/4885GABRA3 23/4885 |
| US-20030045449-A1 | Pharmaceutical combinations for the treatment of neurodegenerative diseases | GRIN3A, GRIN1, CHRNA10 | GABRG2 152/4885GABRB3 89/4885GABRA3 132/4885 |
| US-10485814-B2 | Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof | NNT, CS, ME2 | GABRG2 3777/4885GABRB3 2740/4885GABRA3 3221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.